DK0472327T3 - Præparat på form af øjendråber - Google Patents

Præparat på form af øjendråber

Info

Publication number
DK0472327T3
DK0472327T3 DK91307275.7T DK91307275T DK0472327T3 DK 0472327 T3 DK0472327 T3 DK 0472327T3 DK 91307275 T DK91307275 T DK 91307275T DK 0472327 T3 DK0472327 T3 DK 0472327T3
Authority
DK
Denmark
Prior art keywords
eye drops
preparation
benzoxadine
thioxo
cyclodextrin
Prior art date
Application number
DK91307275.7T
Other languages
Danish (da)
English (en)
Inventor
Kazumichi Ushio
Yoshifumi Ikejiri
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Application granted granted Critical
Publication of DK0472327T3 publication Critical patent/DK0472327T3/da

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK91307275.7T 1990-08-13 1991-08-08 Præparat på form af øjendråber DK0472327T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21482790 1990-08-13
JP16285491 1991-07-03

Publications (1)

Publication Number Publication Date
DK0472327T3 true DK0472327T3 (da) 1995-05-08

Family

ID=26488494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91307275.7T DK0472327T3 (da) 1990-08-13 1991-08-08 Præparat på form af øjendråber

Country Status (16)

Country Link
US (1) US5663170A (es)
EP (1) EP0472327B1 (es)
JP (1) JP2769253B2 (es)
KR (1) KR920003971A (es)
AT (1) ATE121295T1 (es)
AU (1) AU633754B2 (es)
CA (1) CA2048942A1 (es)
DE (1) DE69109021T2 (es)
DK (1) DK0472327T3 (es)
ES (1) ES2071227T3 (es)
FI (1) FI97777C (es)
HU (1) HU207950B (es)
NO (1) NO177845C (es)
PT (1) PT98643B (es)
RU (1) RU2068260C1 (es)
TW (1) TW200402B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018764A2 (en) * 1992-03-18 1993-09-30 Coopervision Pharmaceuticals, Inc. VERAPAMIL HCl FORMULATION AND OTHER OPHTHALMIC SOLUTIONS WITH BUFFER SYSTEM FOR OCULAR ADMINISTRATION
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
WO1994010976A1 (en) * 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Polyvinyl alcohol/borate ophthalmic drug delivery system
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
WO1995003784A1 (en) * 1993-07-28 1995-02-09 Insite Vision Incorporated Suspensions for delivery of medicament
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
CA2192965C (en) * 1994-07-11 2007-12-04 David W. Pate Anandamide analogue compositions and method of treating intraocular hypertension using same
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
KR100261585B1 (ko) * 1995-01-20 2000-07-15 오쿠다 기요아키 항염증점안제
ATE215821T1 (de) * 1995-01-20 2002-04-15 Wakamoto Pharma Co Ltd Entzündungshemmende augentropfen
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
ES2263623T3 (es) * 2000-06-19 2006-12-16 Santen Pharmaceutical Co., Ltd. Agentes antisepticos.
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
JPWO2006137433A1 (ja) * 2005-06-21 2009-01-22 わかもと製薬株式会社 レボカバスチンを可溶化させた水性薬剤
US20100069335A1 (en) * 2005-07-15 2010-03-18 Rajiv Bhushan Prevention and Treatment of Ophthalmic Complications of Diabetes
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
CN112272578A (zh) * 2018-04-27 2021-01-26 阿勒根公司 抗微生物功效增强且毒性降低的亚氯酸钠组合物
CN114746079A (zh) * 2019-11-21 2022-07-12 三进制药株式会社 用于预防或治疗眼部疾病的滴眼剂组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602641B2 (en) * 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use

Also Published As

Publication number Publication date
US5663170A (en) 1997-09-02
FI913811A0 (fi) 1991-08-12
ATE121295T1 (de) 1995-05-15
TW200402B (es) 1993-02-21
FI913811A (fi) 1992-02-14
EP0472327B1 (en) 1995-04-19
NO913136L (no) 1992-02-14
DE69109021T2 (de) 1995-09-21
ES2071227T3 (es) 1995-06-16
PT98643B (pt) 1999-01-29
EP0472327A1 (en) 1992-02-26
FI97777B (fi) 1996-11-15
DE69109021D1 (de) 1995-05-24
HU207950B (en) 1993-07-28
FI97777C (fi) 1997-02-25
JP2769253B2 (ja) 1998-06-25
JPH05213757A (ja) 1993-08-24
HU912692D0 (en) 1992-01-28
NO177845B (no) 1995-08-28
PT98643A (pt) 1992-07-31
AU633754B2 (en) 1993-02-04
NO177845C (no) 1995-12-06
KR920003971A (ko) 1992-03-27
AU8170891A (en) 1992-02-20
HUT61196A (en) 1992-12-28
NO913136D0 (no) 1991-08-12
CA2048942A1 (en) 1992-02-14
RU2068260C1 (ru) 1996-10-27

Similar Documents

Publication Publication Date Title
DK0472327T3 (da) Præparat på form af øjendråber
DE69010139D1 (de) Haarkräftigungsmittel.
DE69121211T2 (de) Applanationstonometer
DE69116705T2 (de) Antiglancoma-Zusammensetzungen enthaltend 3-Arylcarbonyl-1-aminoalkyl-1H-indol
DK0400522T3 (da) Fremgangsmåde til fremstilling af mikroniserede bionedbrydelige partikler
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
DK0443848T3 (da) Nyt antiulcermiddel
DE69231883D1 (de) 4-(1,1-Dialkoxycarbonyl-Alkyl)Azetidin-2-on-Derivate zur Herstellung von 4-(1-Carboxy-Alkyl)Azetidin-2-on-Derivaten
ZA834409B (en) 1,4-dihydropyridine derivatives in optically active or in racemate form and their production and pharmaceutical compositions
MX9101831A (es) Composiciones de dextrometorfano contra la tos
DE59104649D1 (de) Verfahren zur Herstellung von N,N,N',N'-Tetraglycidyl-3,3'-dialkyl-4,4'-diaminodiphenylmethanen.
DE69107897T2 (de) Verfahren zur Herstellung von N,N'-bis(tetrabromophthalimid).
DE59105920D1 (de) Verfahren zur Herstellung von 5-Hydroxy-3,4,5,6-tetrahydro-pyrimidin-Derivaten.
DK81890A (da) 2-hydrozy-n,n,n-trimethylethanaminiumsalte af 5 beta-cholan-24-syrederivater
FR2671085B1 (fr) Preparation d'amidures manganeux.
IT9018403U1 (it) Atomizzatore "elicomma".